AI Engines For more Details: Perplexity Kagi Labs You
Neurological Disorders: Inosine has been investigated for its potential neuroprotective effects and its role in promoting neuroplasticity. Research suggests that inosine supplementation may enhance recovery from neurological injuries, such as stroke and traumatic brain injury, by promoting axonal sprouting, synaptic plasticity, and neuronal survival. Inosine may also modulate neurotransmitter systems and have implications for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Cardiovascular Health: Inosine has been studied for its effects on cardiovascular function and may have potential benefits for heart health. It is involved in regulating vascular tone, platelet aggregation, and endothelial function. Inosine supplementation has been investigated as a potential therapy for conditions such as myocardial infarction, heart failure, and peripheral artery disease, although more research is needed to establish its efficacy and safety in these contexts.
Immune Function: Inosine plays a role in modulating immune responses and inflammation. It has been studied for its immunomodulatory effects and its potential to enhance immune function in conditions such as autoimmune diseases, infections, and cancer. Inosine may influence the activity of immune cells, cytokine production, and inflammatory pathways, although further research is needed to fully understand its mechanisms and therapeutic implications.
Muscle Performance: Inosine supplementation has been investigated for its potential to improve muscle performance and exercise capacity. It is thought to act as a precursor to adenosine triphosphate (ATP), the primary energy currency of cells, and may enhance energy metabolism and muscle contractility during exercise. Some studies have suggested that inosine supplementation may increase endurance, reduce fatigue, and improve recovery in athletes and individuals undergoing physical training.
Neurological Regeneration: Inosine has been studied for its potential to promote neural regeneration and repair in the central nervous system. It may stimulate the growth of axons and dendrites, enhance synaptic plasticity, and support the survival of neurons and glial cells. Inosine supplementation has been investigated in preclinical models of spinal cord injury, multiple sclerosis, and other neurological disorders, with promising results suggesting its potential as a therapeutic agent for promoting neural recovery.
Metabolic Disorders: Inosine metabolism is linked to various metabolic pathways, including purine metabolism and energy metabolism. Alterations in inosine levels have been observed in metabolic disorders such as gout, hyperuricemia, and metabolic syndrome. Inosine supplementation may modulate metabolic processes and have implications for conditions related to energy metabolism, although more research is needed to clarify its effects in these contexts.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
| species | Lactobacillus acidophilus | Increases |
| species | Lactobacillus crispatus | Increases |
| species | Lactobacillus gasseri | Increases |
| species | Lactobacillus helveticus | Increases |
| species | Lactobacillus jensenii | Increases |
| species | Lactobacillus johnsonii | Increases |
| species | Lactobacillus kefiranofaciens | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | 0 |
| Acne | 0.9 | 0.3 | 2 |
| ADHD | 2.1 | 1.1 | 0.91 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 1.1 | -0.83 |
| Allergies | 1.9 | 0.7 | 1.71 |
| Allergy to milk products | 0.6 | 2 | -2.33 |
| Alopecia (Hair Loss) | 0.5 | 0.2 | 1.5 |
| Alzheimer's disease | 2.7 | 3.3 | -0.22 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 3.2 | -7 |
| Ankylosing spondylitis | 2.2 | 1.4 | 0.57 |
| Anorexia Nervosa | 1.3 | 0.3 | 3.33 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.2 | 1.5 |
| Asthma | 2.1 | 0.9 | 1.33 |
| Atherosclerosis | 0.8 | 1.2 | -0.5 |
| Atrial fibrillation | 1.4 | 1.4 | 0 |
| Autism | 4.4 | 4.3 | 0.02 |
| Barrett esophagus cancer | 0 | 0 | |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Bipolar Disorder | 0.6 | 1.6 | -1.67 |
| Brain Trauma | 2.5 | 0.5 | 4 |
| Breast Cancer | 0.2 | 0.2 | |
| Carcinoma | 1.4 | 1.6 | -0.14 |
| Celiac Disease | 2.7 | 1.3 | 1.08 |
| Cerebral Palsy | 1.2 | 0.8 | 0.5 |
| Chronic Fatigue Syndrome | 1.7 | 2 | -0.18 |
| Chronic Kidney Disease | 0.8 | 1.2 | -0.5 |
| Chronic Lyme | 0.6 | 0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.8 | -0.33 |
| Chronic Urticaria (Hives) | 0.8 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.9 | 0.2 | 3.5 |
| Colorectal Cancer | 1 | 2.3 | -1.3 |
| Constipation | 1 | 1.8 | -0.8 |
| Coronary artery disease | 0.4 | 0.4 | 0 |
| COVID-19 | 6 | 3.5 | 0.71 |
| Crohn's Disease | 4.1 | 3.9 | 0.05 |
| cystic fibrosis | 1.4 | 1.4 | |
| deep vein thrombosis | 0.9 | 0.9 | |
| Depression | 5.6 | 6.2 | -0.11 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0.5 | 0.8 | -0.6 |
| Endometriosis | 1.6 | 1.2 | 0.33 |
| Eosinophilic Esophagitis | 0.3 | 0 | 0 |
| Epilepsy | 2.8 | 2.8 | 0 |
| erectile dysfunction | 0.6 | 0.2 | 2 |
| Fibromyalgia | 1.4 | 0.5 | 1.8 |
| Functional constipation / chronic idiopathic constipation | 2.6 | 3.2 | -0.23 |
| gallstone disease (gsd) | 0.4 | 1.1 | -1.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.9 | -1.25 |
| Generalized anxiety disorder | 0.9 | 0 | 0 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 1 | 1 | |
| Gout | 0.6 | -0.6 | |
| Graves' disease | 0.3 | 2.3 | -6.67 |
| Halitosis | 1.1 | -1.1 | |
| Hashimoto's thyroiditis | 1.3 | 1.4 | -0.08 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.2 | -0.2 | |
| Hidradenitis Suppurativa | 0.2 | -0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | -1 | |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.5 | -0.25 |
| hyperglycemia | 2.5 | 0.5 | 4 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.7 | 0.71 |
| hypersomnia | 0.4 | 0.2 | 1 |
| hypertension (High Blood Pressure | 3.4 | 2.6 | 0.31 |
| Hypothyroidism | 1 | 1 | 0 |
| Hypoxia | 0.2 | 1.8 | -8 |
| IgA nephropathy (IgAN) | 1.8 | 1.8 | |
| Inflammatory Bowel Disease | 3.1 | 2.1 | 0.48 |
| Insomnia | 1.9 | 2.2 | -0.16 |
| Intelligence | 1.2 | 1 | 0.2 |
| Intracranial aneurysms | 0.8 | 2.3 | -1.87 |
| Irritable Bowel Syndrome | 2.6 | 3.7 | -0.42 |
| Liver Cirrhosis | 2.8 | 3 | -0.07 |
| Long COVID | 5.1 | 4.8 | 0.06 |
| Low bone mineral density | 0.8 | 0.8 | |
| Lung Cancer | 1.3 | 0.4 | 2.25 |
| ME/CFS with IBS | 0.8 | 0.8 | |
| ME/CFS without IBS | 0.6 | 0.2 | 2 |
| Menopause | 0.2 | -0.2 | |
| Metabolic Syndrome | 4.4 | 6 | -0.36 |
| Mood Disorders | 5.6 | 7.6 | -0.36 |
| multiple chemical sensitivity [MCS] | 1.2 | -1.2 | |
| Multiple Sclerosis | 2.4 | 2.9 | -0.21 |
| Multiple system atrophy (MSA) | 0.2 | 1.4 | -6 |
| Neuropathy (all types) | 0.3 | 1.5 | -4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.3 | -0.5 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 0.6 | 3 |
| Obesity | 3.7 | 3.6 | 0.03 |
| obsessive-compulsive disorder | 2 | 1.6 | 0.25 |
| Osteoarthritis | 0.6 | 0.6 | 0 |
| Osteoporosis | 2 | 2.2 | -0.1 |
| pancreatic cancer | 0.8 | -0.8 | |
| Parkinson's Disease | 2.7 | 2.9 | -0.07 |
| Polycystic ovary syndrome | 0.8 | 2.9 | -2.62 |
| primary biliary cholangitis | 0.8 | 0.8 | |
| Psoriasis | 1.4 | 2 | -0.43 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 5.1 | -0.76 |
| Rosacea | 1.1 | 0.2 | 4.5 |
| Schizophrenia | 0.6 | 3.9 | -5.5 |
| scoliosis | 0.4 | 0.8 | -1 |
| Sjögren syndrome | 1.4 | 0.6 | 1.33 |
| Sleep Apnea | 0.8 | 1 | -0.25 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | -0.8 | |
| Stress / posttraumatic stress disorder | 1.4 | 1.8 | -0.29 |
| Systemic Lupus Erythematosus | 2.6 | 2.8 | -0.08 |
| Tic Disorder | 0.8 | 1.2 | -0.5 |
| Tourette syndrome | 1.8 | 0.8 | 1.25 |
| Type 1 Diabetes | 1.1 | 2 | -0.82 |
| Type 2 Diabetes | 3.7 | 5.6 | -0.51 |
| Ulcerative colitis | 4.1 | 2.6 | 0.58 |
| Unhealthy Ageing | 1.4 | 1.4 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.